100
Participants
Start Date
April 10, 2025
Primary Completion Date
January 25, 2026
Study Completion Date
January 25, 2026
1 blood sample, 40 mL (collection during a blood test, part of the standard of care for this disease)
Mononuclear and polynuclear peripheral blood cells from subjects suffering from IMID will be exposed in vitro to different inflammatory inducers with and without the concomitant addition of at least 4 different pCB extracts spectrum complete (full spectrum) including a dominant CBD extract and low in THC (\<0.2%), 1 dominant THC extract, 1 balanced THC/CBD extract and 1 dominant CBG extract. The same analyzes will be carried out in the presence of a recognized anti-inflammatory (for example hydrocortisone or dexamethasone) which will thus be used as a positive control.
RECRUITING
CHU d'ORLEANS, Orléans
Centre Hospitalier Régional d'Orléans
OTHER